Navigation Links
Luminex Corporation Third Quarter Earnings Release Scheduled for November 1, 2011
Date:10/11/2011

AUSTIN, Texas, Oct. 11, 2011 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it expects to report results for the third quarter of 2011 on Tuesday, November 1, 2011.  A press release announcing the results is scheduled for release after the close of trading.

(Logo:  http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Management will hold a conference call to discuss the operating highlights and financial results for the third quarter ended September 30, 2011, at 5:00 p.m. Eastern time on November 1, 2011.

The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at http://www.luminexcorp.com.  Simply log on to the website, go to the About Us section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software.  If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

The use of pop-up blocking software may impair your ability to view webcasts.  If you use this software, press and hold the CTRL key when you click on the Register button.  Please contact your IT group if you are unable to override this feature.  Unauthorized recording or downloading of this event is not permitted.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP technology can be obtained at www.luminexcorp.com.

Statements made in this release that express Luminex Corporation's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements. Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies or selected assets into our consolidated business operations, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission. The forward-looking statements contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Luminex Corporate Contact:

Harriss T. Currie
Chief Financial Officer and Vice President, Finance
512-219-8020
hcurrie@luminexcorp.com

Luminex Investor Relations Contact:

Matthew D. Scalo
Sr. Director of Investor Relations
512-219-8020
mscalo@luminexcorp.com


'/>"/>
SOURCE Luminex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna
2. Luminex Corporation to Present at Upcoming Investment Conferences In September
3. Luminex Corporation Reports Second Quarter 2011 Results
4. Luminex Corporation Receives U.S. FDA Clearance for New, Front Line Respiratory Viral Panel Test
5. Luminex Corporation Second Quarter Earnings Release Scheduled for August 8, 2011
6. Luminex Corporation Completes Acquisition of EraGen Biosciences, Inc.
7. Luminex Corporation Named Most Innovative Company of the Year and Receives Business Innovation of the Year Award for MAGPIX® System
8. Luminex Corporation Announces Agreement to Acquire EraGen Biosciences, Inc.
9. Luminex and Life Technologies Sign Agreement for Global Distribution of the Award-Winning MAGPIX® Multiplexing Instrument
10. Luminex Corporation to Present at Jefferies 2011 Global Healthcare Conference
11. Luminex Corporation Reports First Quarter 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... -- Medivir AB (Nasdaq Stockholm: MVIR) today ... of Directors that will be submitted to the 2017 ... of the company,s three largest shareholders at the end ... a seat on the Nomination Committee, and the Chairman ... Committee was as follows:  ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... provides drug pricing data and benchmarks in the global Autism Spectrum ... What are the key drugs marketed for Autism ...
(Date:2/23/2017)... ITL Limited, ( ASX: ITD ), an innovative diversified healthcare company, ... 31 December 2016 compared with the previous corresponding period. A full ... here . Highlights Profit ... Earnings per share of 2.2 cents (Dec 2015: 1.2 cents; ... up 11%) Profit before tax of $2.12m (Dec ...
Breaking Medicine Technology:
(Date:2/24/2017)... TX (PRWEB) , ... February 24, 2017 , ... ... offering promotions on tooth replacement options at his office, Antoine Dental Center. Currently, ... implants for $18,499. Some restrictions may apply, but patients can learn more about ...
(Date:2/24/2017)... PA (PRWEB) , ... February 24, 2017 , ... An ... researchers at the University of Pittsburgh points to eight genes that may explain why ... other, according to the results of a study published today in the journal npj ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT ... top priority because it’s not if you will be attacked, but when.” However, he ... comes to digital health care. , Improvements in auditing and monitoring have taken security ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ ... Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes the tragedies he ... and his attempts to overcome them. , Schanssema, initially unsure of the career path ...
(Date:2/24/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... Yisrayl makes an astounding statement when he says that the entire Bible was written ... the current times so plainly that anyone should be able to see the time ...
Breaking Medicine News(10 mins):